These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency.
    Author: Yang Z, Wang L, Wang H, Shang X, Niu W, Li J, Wu Y.
    Journal: Mol Immunol; 2008 Mar; 45(6):1674-81. PubMed ID: 18035418.
    Abstract:
    Numerous evidences have indicated that CD8+ cytotoxic T lymphocytes (CTLs) played a significant role in protecting host against tumors, thus CTLs have been involved as potentially relevant candidate targets of cancer immunotherapy. Moreover it is crucial to fully elucidate antigen-specific CTL response, especially high-avidity and long-lasting CTL response in vivo. In the present study, we reported a novel tumor vaccine (mimovirus), a viron-size particulate which consisted of a cell-penetrating peptide of Tat(49-57), a CTL epitope peptide survivin(85-93) and a plasmid encoding murine interleukin-15 (IL-15). We demonstrated that this tumor vaccine could effectively mediate the expression of the gene and presentation of the tumor antigen derived peptide ex vivo. Furthermore, the tumor vaccine supported a robust memory CTL-mediated long-term immunity in vivo, which could effectively protect BALB/c mice against fatal CT26 tumor challenge and improve their survival. These findings suggest that the tumor vaccine may provide an alternative therapeutic strategy for cancer patients.
    [Abstract] [Full Text] [Related] [New Search]